Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Submitted by
admin
on June 26, 2017 - 5:15pm
Source:
Reuters
News Tags:
Novo Nordisk
obesity
semaglutide
Headline:
Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Do Not Allow Advertisers to Use My Personal information
